- Home
- BMRN vs MBLY Comparison
BMRN vs MBLY Comparison
Compare BMRN & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | MBLY |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.3B |
| IPO Year | 1999 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BMRN | MBLY |
|---|---|---|
| Price | $53.19 | $11.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $88.42 | $19.29 |
| AVG Volume (30 Days) | 3.0M | ★ 4.0M |
| Earning Date | 10-27-2025 | 10-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.53 | N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $3,094,001,000.00 | $1,938,000,000.00 |
| Revenue This Year | $13.39 | $15.90 |
| Revenue Next Year | $7.57 | $7.88 |
| P/E Ratio | $19.92 | ★ N/A |
| Revenue Growth | ★ 12.39 | 7.61 |
| 52 Week Low | $50.76 | $10.74 |
| 52 Week High | $73.51 | $22.51 |
Technical Indicators
Market Signals| Indicator | BMRN | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 42.39 |
| Support Level | $53.03 | $10.93 |
| Resistance Level | $54.66 | $11.87 |
| Average True Range (ATR) | 1.45 | 0.42 |
| MACD | -0.11 | 0.12 |
| Stochastic Oscillator | 31.61 | 61.61 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.